- Home
- SLM vs GH Comparison
SLM vs GH Comparison
Compare SLM & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLM
- GH
- Stock Information
- Founded
- SLM 1972
- GH 2011
- Country
- SLM United States
- GH United States
- Employees
- SLM N/A
- GH N/A
- Industry
- SLM Finance: Consumer Services
- GH Medical Specialities
- Sector
- SLM Finance
- GH Health Care
- Exchange
- SLM Nasdaq
- GH Nasdaq
- Market Cap
- SLM 7.2B
- GH 4.9B
- IPO Year
- SLM N/A
- GH 2018
- Fundamental
- Price
- SLM $32.37
- GH $40.62
- Analyst Decision
- SLM Buy
- GH Strong Buy
- Analyst Count
- SLM 11
- GH 21
- Target Price
- SLM $31.55
- GH $52.81
- AVG Volume (30 Days)
- SLM 2.0M
- GH 2.3M
- Earning Date
- SLM 07-23-2025
- GH 04-30-2025
- Dividend Yield
- SLM 1.61%
- GH N/A
- EPS Growth
- SLM N/A
- GH N/A
- EPS
- SLM 2.78
- GH N/A
- Revenue
- SLM $1,449,130,000.00
- GH $773,996,000.00
- Revenue This Year
- SLM $7.60
- GH $23.05
- Revenue Next Year
- SLM $9.61
- GH $21.40
- P/E Ratio
- SLM $11.63
- GH N/A
- Revenue Growth
- SLM N/A
- GH 28.20
- 52 Week Low
- SLM $19.39
- GH $20.14
- 52 Week High
- SLM $34.55
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- SLM 53.17
- GH 48.45
- Support Level
- SLM $32.52
- GH $37.73
- Resistance Level
- SLM $34.55
- GH $39.63
- Average True Range (ATR)
- SLM 0.83
- GH 1.60
- MACD
- SLM -0.22
- GH -0.01
- Stochastic Oscillator
- SLM 11.38
- GH 60.00
About SLM SLM Corporation
SLM Corp is an education solutions company. It business is to originate and service loans to students and their families to finance the cost of their education. The provide Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.